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Activation of the type I insulin-like growth factor receptor (IGF-IR) regulates several aspects of the malignant phenotype, including
cancer cell proliferation and metastasis. Phosphorylation of adaptor proteins downstream of IGF-IR may couple IGF action to specific
cancer phenotypes. In this study, we sought to determine if insulin receptor substrate-1 and -2 (IRS-1 and -2) mediate distinct
biological effects in breast cancer cells. Insulin receptor substrate-1 and IRS-2 were expressed in T47D-YA breast cancer cells, which
lack IRS-1 and -2 expression, yet retain functional IGF-IR. In the absence of IRS-1 and -2 expression, IGF-IR activation was unable to
stimulate proliferation or motility in T47D-YA cells. Expression of IRS-1 resulted in IGF-I-stimulated proliferation, but did not affect
motility. In contrast, expression of IRS-2 enhanced IGF-I-stimulated motility, but did not stimulate proliferation. The aIR-3, an inhibitor
of the IGF-IR, was unable to affect these IGF-stimulated phenotypes unless IRS-1 or -2 was expressed. Thus, IGF-IR alone is unable to
regulate important breast cancer cell phenotypes. In these cells, IRS proteins are required for and mediate distinct aspects of IGF-IR-
stimulated behaviour. As multiple agents targeting the IGF-IR are currently in early clinical trials, IRS expression should be considered
as a potential biomarker for IGF-IR responsiveness.
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The evidence implicating the insulin-like growth factor (IGF)
system in breast cancer progression suggests that the type I IGF
receptor (IGF-IR) may be a viable target for the treatment of breast
cancer (Byron and Yee, 2003; Ibrahim and Yee, 2005). Indeed, IGF-
IR inhibition, using either dominant negative or pharmacological
approaches, has been shown to inhibit breast tumour growth and
metastasis both in vitro and in vivo (Arteaga et al, 1989; Arteaga
and Osborne, 1989; Burtrum et al, 2003; Sachdev et al, 2003;
Sachdev et al, 2004). Given these findings, multiple agents
targeting IGF-IR have been developed, with several agents
currently in early clinical trials (Garber, 2005). However, as
illustrated by the development of the EGFR inhibitor, gefitinib,
clinical trial design is crucial towards accurately assessing the
effectiveness of a therapeutic approach. In two recent phase II
trials in patients with refractory metastatic breast cancer, the EGFR
inhibitor gefitinib showed minimal to no clinical activity (Baselga
et al, 2005; von Minckwitz et al, 2005). However, this lack of
significant clinical activity was not owing to lack of receptor
inhibition in these tumours, but rather to lack of EGFR
dependence in the tested population (Baselga et al, 2005).
This raises an important question: what molecular attributes will
likely be predictive of tumour dependence on IGF-IR? Clearly, IGF-
IR expression will be required for response to agents that target the
IGF-IR. However, this may not be sufficient to accurately identify
breast tumours dependent on IGF-IR. As adaptor molecules are
important components of IGF-IR signalling (Zhang and Yee, 2000;
Sachdev and Yee, 2001), we propose that expression of the
appropriate adaptor molecules, in addition to a functional
receptor, may be necessary to observe a therapeutic response to
agents targeting IGF-IR.
Although multiple proteins are involved in IGF-IR signal
transduction, the insulin receptor substrate (IRS) molecules are
the primary family of adaptor proteins used by the IGF-IR. Though
six IRS family members have been identified (IRS-1 to IRS-6)
(White et al, 1985; Tobe et al, 1995; Lavan et al, 1997a,b; Cai et al,
2003), IRS-1 and -2 are the predominant signalling molecules
utilised by the IGF-IR to mediate IGF-I action in breast cancer cells
(Jackson et al, 1998, 2001). Indeed, human breast tumours express
both IRS-1 and -2 (Jackson et al, 1998; Lee et al, 1999).
Previous work from our lab and others suggests that IRS-1 and
-2 may mediate different aspects of IGF-IR action in breast cancer
cells in vitro. Insulin receptor substrate-1 is the predominant
signalling molecule activated in MCF-7 breast cancer cells in
response to IGF-I stimulation and this activation is required for
IGF-I-stimulated cell proliferation of these cells (Jackson et al,
1998). In contrast, breast cancer cells selected for metastatic
behaviour in vivo have increased IRS-2 activation (Jackson et al,
2001). In these cells, IGF-IR activation enhanced cell adhesion and
motility, suggesting that IRS-2 may mediate these aspects of the
malignant phenotype. Thus, IRS-1 activation may correlate with
proliferation, whereas IRS-2 may couple to cell migration. These
observations may have important clinical implications towards
predicting response to anti-IGF-IR strategies. However, these
studies merely correlate IGF-IR biology with individual IRS
species; studies that directly determine whether IRS-1 and -2
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needed.
Herein, we sought to determine whether IGF-IR requires IRS-1
and -2 to transduce its biological effects, and whether these IRS
proteins mediate distinct aspects of IGF-IR action in breast cancer
cells. For these studies, we identified a new cell line to study IRS-
dependent effects, the T47D-YA breast cancer cell line. These cells
lack IRS-1 and -2 expression, yet express functional IGF-IR,
allowing us to investigate whether IGF-IR activation stimulates
cell proliferation and motility in the absence of IRS-1 and -2.
Furthermore, to determine whether IRS-1 and -2 mediate distinct
aspects of IGF-IR biology, we stably expressed IRS-1 or -2 proteins
in T47D-YA cells and examined biological responsiveness.
Here, we report that the IGF-IR is unable to mediate biological
effects in the absence of IRS-1 and -2 expression, and directly
demonstrate that these adaptor molecules mediate distinct aspects
of IGF-IR action in breast cancer cells. Furthermore, we propose
that expression of IRS adaptor molecules may function as a
biomarker for biological responsiveness of the IGF-IR.
MATERIALS AND METHODS
Cell culture and reagents
The establishment of the T47D series of breast cancer cell lines
occurred in the laboratory of Kathryn Horwitz and has been
described previously (Sartorius et al, 1994). The T47D-WT, T47D-
CO and T47D-Y human breast cancer cells were maintained in
Eagle’s Minimal Essential Medium supplemented with 5% foetal
bovine serum, 6ngl
 1 insulin and 10mll
 1 100X non-essential
amino acids. The T47D-YA and T47D-YB cells were maintained in
the above medium with 200mgml
 1 of G418. Growth media for
T47D-YA IRS-1 and T47D-YA IRS-2 cells was also supplemented
with 200mgml
 1 hygromycin. Cells were serum-starved in phenol-
red free serum-free media (Improved MEM Zinc Option,
supplemented with 20mm HEPES, 1X Trace Elements, 2mgml
 1
transferrin, and, for IGF-I stimulation, 2mgml
 1 fibronectin). All
cells were grown at 371C in a humidified atmosphere containing
5% CO2. The aIR-3 (IGF-I receptor Ab-1) was purchased from
Calbiochem (San Diego, CA, USA). Insulin-like growth factor-I was
purchased from GroPep (Adelaide, Australia) and culture media
and fibronectin were purchased from Invitrogen Corporation
(Carlsbad, CA, USA).
Stable transfection
Hemagglutinin-tagged human IRS-1 and -2 cDNAs driven by a
CMV promoter in a pcDNA3.1 (–) vector were generously
supplied by Adrian Lee (Baylor College of Medicine). Stable IRS-
1 and -2 cell clones were generated by co-transfection of T47D-YA
cells with IRS-1 or -2 cDNA and pcDNA3.1(–) Hygro
R (Invitrogen,
Grand Island, NY, USA). Effectene transfection reagent and
protocol were followed. Briefly, 8 10
5 cells were plated into
60mm plates and grown to 50% confluence. Cells were then
co-transfected with a 20:1 ratio of human IRS-1 or -2 cDNA to
plasmid encoding hygromycin resistance and single colonies
expanded following antibiotic selection in 200mgml
 1 hygromy-
cin. Positive clones were selected based on positive immunoblot
detection of IRS-1 or -2 and the HA tag (data not shown).
Lysate preparation
Cells were plated in growth medium in a 100mm dish and grown
to 70% confluency. For IGF-I stimulation, cells were washed twice
with phosphate-buffered saline (PBS), serum-deprived in serum-
free media (SFM) for 24h and then stimulated with 5nM IGF-I in
SFM for 10min at 371C. Cells were washed twice with ice-cold PBS
on ice and lysed with 500ml TNESV lysis buffer (50mM Tris-Cl (pH
7.4), 1% NP40, 2mM EDTA (pH 8.0), 100mM NaCl, 10mM sodium
orthovanadate, 1mM phenylmethylsulfonyl fluoride, 20mgml
 1
leupeptin and 20mgml
 1 aprotinin). Lysates were cleared by
20min of centrifugation at 12000 g at 41C. Protein concentra-
tions of the lysates were determined using the bicinchoninic acid
kit (Pierce, Rockford, IL, USA).
Immunoblot
Total cell lysates (40mg) in 1X Laemmli sample buffer were
separated using 8% SDS-PAGE and transferred to nitrocellulose.
Nitrocellulose membranes were blocked with 5% non-fat dry milk
in TBST (0.05% Tween in Tris-buffered saline w/v) for 1h at room
temperature. Primary antibodies were used according to the
manufacturer’s direction. Insulin receptor substrate-1 (produced
by Alpha Diagnostics, San Antonio, TX, USA and protein A
agarose affinity purified, as described previously (Sachdev et al,
2003)), IRS-2 (Upstate lot #21189, Charlottesville, VA, USA) and
IGF-IR (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)
antibodies were used at 1:2000 in 5% milk overnight at 41C. Total
ERK1/2 MAPK (Cell Signaling Technology, Beverly, MA, USA),
phosphorylated ERK1/2 MAPK (Thr202/Tyr204) (Cell Signaling
Technology, Beverly, MA, USA), and total Akt (Cell Signaling
Technology, Beverly, MA, USA) antibodies were used at 1:2000 in
TBST overnight at 41C. Phosphorylated Akt (Ser473) (Cell
Signaling Technology, Beverly, MA, USA) was used at 1:2000 in
1% BSA overnight at 41C. Following incubation with primary
antibody, membranes were washed in TBST six times for 5min
each and incubated for 1h at room temperature with 1:2000
dilution of horseradish peroxide (HRP)-linked anti-rabbit second-
ary antibody (Amersham, Piscataway, NJ, USA) in 5% milk.
Horseradish peroxide (HRP)-conjugated PY-20 antibody (BD
Biosciences, San Jose, CA, USA) was used at 1:10000 in TBST
for 1h at room temperature. Membranes were washed six times for
5min each and chemiluminescence detected using SuperSignal
West Pico substrate (Pierce, Rockford, IL, USA). In each
experiment, total MAPK levels were determined as a loading
control (data not shown).
Immunoprecipitation
Total cellular lysates (1000mg) were pre-cleared with 50ml protein
A agarose (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
Precleared lysates were incubated overnight at 41C with IRS-1,
IRS-2 or IGF-IR antibody. The next day 50ml protein A agarose
was added for 4h at 41C. Immunoprecipitates were collected by
centrifugation at 12000 g for 5min at 41C, and washed five times
in TNESV buffer. Samples were resuspended in sample buffer,
boiled for 5min, and analysed by SDS-PAGE followed by
immunoblotting for phosphorylated tyrosine residues with an
HRP-conjugated PY-20 antibody, as described above.
Monolayer growth assay
Assays were performed as previously described (Twentyman and
Luscombe, 1987). Briefly, cells were plated in triplicate in 24-well
tissue culture plates at a density of 10000 cells per well in growth
media. After 24h, cells were washed twice with PBS and switched
to SFM for 24h. Cells were then treated with or without 5nM IGF-I
in SFM and incubated for 6 days. For aIR-3 experiments, cells
were treated with 3mgml
 1 aIR-3, 5nM IGF-I or 3mgml
 1 aIR-3
plus 5nM IGF-I. Cell number was estimated using the 3-[4,5-
dimethyllthiazol 2-yl]2,5-diphenyltetrazolium bromide (MTT)
assay. Sixty microlitres of 5mgml
 1 MTT reagent in SFM was
added to each well and plates incubated for 3h at 371C. Wells were
then aspirated and 0.5ml of solubilising solution (95%
DMSOþ5% IMEM) added to solubilise the formazan crystals.
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filter.
Cell cycle analysis
Cells were plated at a density of 0.5 10
6 cells per 60mm dish.
After 24h, cells were washed twice with PBS and switched to SFM
for 48h. Cells were then treated with or without 5nM IGF-I in SFM
for 24h, collected on ice in 1ml of PBS and stained with propidium
iodide solution (Krishan, 1975). Cells were analysed for phase of
the cell cycle by flow cytometry. Resulting histograms were
evaluated using Modfit software.
Anchorage-independent growth
Anchorage-independent growth assays were performed as pre-
viously described (Figueroa et al, 1993). Briefly, a bottom agar was
prepared by solidifying 1ml of 0.8% SeaPlaque agarose (BioWhi-
taker, Rockland, ME, USA) in 1% FBS-containing growth media in
each well of a six-well plate. The bottom agar was overlaid with
800ml of a 0.45% top agar mixture containing 10000 cells per well
in the presence or absence of 5nM IGF-I treatment and plates
incubated at 371C. After 14 days, colonies were counted using a
light microscope with an ocular grid. Only colonies larger than
two-thirds of a grid square were counted. Five random fields were
counted for each well and fold increase over samples with no IGF-I
treatment presented.
Gold particle assay
Cell motility was measured using a gold particle phagokinetic
assay, as previously described (Albrecht-Buehler, 1977; Meyer
et al, 2001). Briefly, glass coverslips were pre-coated with 1.5ml of
a5 mgml
 1 solution of fibronectin in SFM overnight at 41C and
then coated with a freshly prepared gold particle solution (10.6mM
sodium carbonate, 12.7mM gold chloride and 0.0087% formalde-
hyde) and incubated overnight at 41C to allow the gold particles to
precipitate. Cells were grown to 70% confluence, briefly trypsi-
nised and 18000 cells were plated per coverslip. The cells were
allowed to adhere, treatment of SFM with or without IGF-I added,
and cells were incubated at 371C in humidified air with 5% CO2 for
24h. For aIR-3 experiments, cells were treated with 3mgml
 1 aIR-
3, 5nM IGF-I or 3mgml
 1 aIR-3 plus 5nM IGF-I for 24h. As the
cells move, the gold particles are internalised, leaving a cleared
area representing the cell track. Cells were then fixed with 3.5%
glutaraldehyde and coverslips mounted on glass slides. Coverslip
images were captured using a brightfield microscope with a neutral
density filter and the area on the coverslip cleared by cell
movement was computed using Simple PCI software.
Insulin receptor substrate-1 short-interfering RNA
IRS-1 and -2 short-interfering RNA (siRNA) were synthesised by
Dharmacon (Lafayette, CO, USA). Four individual sequences were
synthesised, and the IRS-1 sequence that best downregulated IRS-1
was selected. Some sequences did not affect IRS-1 levels and these
are referred to as non-functional (NF) siRNA. Short-interfering
RNA constructs were introduced into MCF-7 cells by lipid
transfection using Effectene (QIAGEN, Valencia, CA, USA). To
determine the effect of IRS-1 downregulation, we transfected
siRNA constructs in triplicate into MCF-7 cells in 96-well plates.
After 6h, the siRNA constructs were removed and cells were
further incubated in SFM overnight. Cells were then exposed to
5n M IGF-I (day 0). Cell number was estimated by MTT assay at
day 0 and after an additional 48h in the presence or absence of
5n M IGF-I. Results are reported as percent increase over day 0.
Statistical analysis
Two-way ANOVA with Bonferroni post-test and Student’s t-test
were performed using GraphPad Prism version 3.02 for Windows
(GraphPad Software, San Diego, CA, USA).
RESULTS
T47D-YA cells lacked insulin-like growth factor-I-
stimulated proliferation and motility, despite expression of
functional insulin-like growth factor receptor
We utilised a series of T47D breast cancer cell lines that
differentially express the two isoforms of the progesterone receptor
(PR). The human PR exists in two isoforms, a B isoform (PR-B)
and an N-terminal truncated A isoform (PR-A), possessing
different transcriptional capacities, despite similar hormone- and
DNA-binding properties (Kastner et al, 1990; Sartorius et al, 1994;
Wen et al, 1994; Richer et al, 2002). T47D cells, here referred to as
T47D-WT cells, express both PR-A and -B in an oestrogen-
dependent manner (Keydar et al, 1979; Sutherland et al, 1992).
T47D-CO cells express both isoforms of PR independent of ER-a
function (Horwitz et al, 1982). T47D-Y cells express neither PR-A
nor PR-B; these cells were transfected with appropriate PR
constructs to obtain variants that express only PR-A (T47D-YA)
or only PR-B (T47D-YB) (Sartorius et al, 1994). These cell lines
were of interest to us as PR-B has been shown to regulate IGF-IR
signalling by ligand-dependent transcriptional upregulation of
IRS-2 (Vassen et al, 1999; Cui et al, 2003). Evidence also suggests
PR-B may regulate IRS-1 expression independent of ligand
(unpublished observations). As PR-B may regulate both IRS-1
and -2 levels, we hypothesised that a PR-B-null-cell line may lack
IRS-1 and -2 expression. Therefore, we first sought to characterise
expression of components of the IGF-IR signalling system in this
series of T47D breast cancer cell lines.
Each of the T47D cell lines expressed levels of IGF-IR similar to
the IGF-I-responsive T47D-WT cell line (Figure 1A). Furthermore,
functional IGF-IR was detected in each of the T47D cell lines
investigated, with T47D-YA and T47D-YB cells exhibiting levels
of activated IGF-IR greater than that of the T47D-WT cells
(Figure 1B). Activation of IGF-IR was less in T47D-Y cells than in
T47D-WT, T47D-YA or T47D-YB cells. We next investigated
expression of IRS-1 and -2 in the T47D cell lines. In the absence of
progestins, T47D-Y and T47D-YA cells lacked IRS-2 protein
expression (Figure 1C). Furthermore, whereas IRS-1 was expressed
in T47D-WT, T47D-CO and T47D-YB cells, neither T47D-Y nor
T47D-YA cells expressed detectable levels of IRS-1 protein
(Figure 1D). Thus, T47D-Y and T47D-YA cells lacked IRS-1 and
-2 expression, yet expressed a functional IGF-IR; T47D-YA cells
were selected for additional study owing to their higher level of
IGF-I-activated IGF-IR.
To determine whether the IGF-IR could mediate biological
responses in the absence of IRS-1 and -2, we next analysed
IGF-I-stimulated proliferation and motility in T47D-YA cells. As
previously reported, IGF-I stimulated monolayer growth in T47D-
WT cells (Figure 1E) (Sutherland et al, 1992). However, T47D-YA
cells were unresponsive to the mitogenic actions of IGF-I.
Furthermore, whereas IGF-I stimulated cell motility of T47D-WT
and MDA-MB-231BO cells (positive control) (Jackson et al, 2001),
IGF-I did not stimulate cell motility in T47D-YA cells (Figure 1F).
Together, these data suggest that IGF-IR activation, in the absence
of IRS-1 and -2, is insufficient to transduce biological signalling.
Furthermore, T47D-YA cells provide an ideal model system to
investigate the roles of IRS-1 and -2 in mediating IGF-IR action, as
these cells lacked IRS-1 and -2 expression and IGF-I-stimulated
proliferation and motility, despite expression of biochemically
functional IGF-IR.
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sInsulin receptor substrate-1, but not insulin receptor
substrate-2, expression resulted in insulin-like growth
factor receptor mediated cell proliferation in T47D-YA
cells
To determine whether expression of IRS-1 and/or IRS-2 could
sufficiently couple IGF-IR to proliferative signalling, T47D-YA
breast cancer cells were stably transfected with cDNA constructs
encoding human IRS-1 or -2. Insulin receptor substrate-1
expression was detected in T47D-YA/IRS-1 clones #5, #8, #10
and #20 (Figure 2A) and IRS-2 expression detected in T47D-YA/
IRS-2 clones #6 and #10 (Figure 2B), which were selected for
subsequent studies. T47D-YA/IRS-2 clone #2 was excluded from
these studies based on positive expression of both IRS-1 and -2
(data not shown). Similar to T47D-YA cells, vector-transfected
control cells had no detectable level of IRS-1 or -2 protein
expression.
We next investigated whether introduction of IRS-1 or -2
expression in T47D-YA cells was sufficient to couple the IGF-IR to
proliferation. As shown in Figure 3A, the T47D-YA/IRS-1 cells
exhibited an increase in monolayer growth upon IGF-I treatment,
similar to T47D-WT cells, demonstrating that introduction of IRS-
1 expression was sufficient to induce IGF-IR-mediated stimulation
of monolayer growth in T47D-YA cells. In contrast, introduction of
IRS-2 expression did not stimulate IGF-IR-mediated monolayer
growth in T47D-YA cells. Similar to T47D-YA cells, vector-
transfected cells did not exhibit IGF-I-stimulated monolayer
growth.
To further demonstrate that IRS-1 couples the IGF-IR to
proliferative pathways, we measured IGF-I-stimulated cell cycle
progression by flow cytometry. As shown in Figure 3B, IGF-I was
unable to stimulate T47D-YA cells to enter S phase of the cell cycle.
However, T47D-YA/IRS-1 cells exhibited IGF-I-stimulated entry
into S phase, similar to T47D-WT cells. In contrast, IGF-I did not
stimulate cell cycle progression in T47D-YA/IRS-2 cells. All cell
lines were growth responsive to medium containing 5% foetal
bovine serum (data not shown). To further investigate IGF-IR-
mediated proliferation of T47D-YA/IRS-1 cells, we assessed
anchorage-independent growth using a soft agar assay. As shown
in Figure 3C, T47D-YA/IRS-1 cells exhibited an IGF-I-stimulated
increase in colony formation, compared to T47D-YA cells. In
contrast, T47D-YA/IRS-2 cells exhibited soft agar growth char-
acteristics similar to T47D-YA cells. Together, these results suggest
that IRS-1 specifically mediates the proliferation signals of the
IGF-IR and that expression of IRS-1 is sufficient to establish
IGF-IR-mediated monolayer and anchorage-independent growth
in T47D-YA cells.
Expression of insulin receptor substrate-2, but not insulin
receptor substrate-1, resulted in insulin-like growth factor
receptor-stimulated motility in T47D-YA cells
Previous work by our lab and others has implicated a role for
IRS-2 in mediating IGF-IR-stimulated cell motility. To investigate
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Figure 1 T47D-YA cells lacked IGF-I-stimulated proliferation and
motility, despite expression of a functional IGF-IR. (A) T47D-WT, T47D-
Y, T47D-YA and T47D-YB cells were serum-deprived for 24h, stimulated
with 5nM IGF-I for 10min, cell lysates separated by 8% SDS-PAGE and
protein levels of the IGF-IR determined by Western blot. (B) T47D cell line
variants were serum-deprived for 24h, stimulated for 10min with 5nM IGF-
I, and cell lysates collected, immunoprecipitated with IGF-IR antibody, and
analysed by immunoblotting with an antibody for phosphorylated tyrosine
residues. (C) T47D-Y and T47D-YA cells were serum-starved for 24h,
stimulated with 5nM IGF-I for 10min, cell lysates separated by 8% SDS-
PAGE and immunoblotted with anti-IRS-2 antibody. MDA-MB-231BO cells
were included as a positive control for IRS-2 expression. (D) T47D-WT,
T47D-CO, T47D-Y, T47D-YA and T47D-YB cells were stimulated with
5n M IGF-I for 10min, cell lysates separated by 8% SDS-PAGE and
immunoblotted with anti-IRS-1 antibody. Experiments were performed
two to four times and representative data shown. (E) T47D-WT and
T47D-YA cells were plated in 24-well plates in growth media, switched to
SFM after 24h, treated with or without 5nM IGF-I for 6 days, and then cell
number estimated using an MTT assay. Error bars represent s.e. of the
mean and * represents a significant difference (Po0.05) in absorbance in
samples treated with IGF-I compared to SFM. P-values: T47D-WT
(P¼0.0409) Results shown are representative of three independent
experiments. (F) T47D-WT and T47D-YA cells were plated on gold
particle-coated coverslips. MDA-MB-231BO cells were included as a
positive control. The cells were allowed to adhere, treatment of SFM with
or without 5nM IGF-I added, and cells incubated at 371 C for 24h.
Coverslip images were captured using a brightfield microscope with a
neutral density filter and the area on the coverslip cleared by cell
movement was computed using Simple PCI software. Data are presented
as mean area cleared. Error bars represent s.e. of the mean and *
represents a significant difference (Po0.05) in samples treated with IGF-I
compared to SFM. P-value: T47D-WT (Po0.001); MDA-MB-231BO
(P¼0.0072). Results shown are representative of three independent
experiments.
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swhether IRS-2 specifically mediates this biological action of the
IGF-IR, we measured IGF-I-stimulated motility of T47D-YA cells
expressing IRS-1 or -2. Although Boyden chambers have been used
to evaluate motility, in this study we used the gold particle assay to
avoid the confounding effects of IGF signalling on cell adhesion
(Zhang et al, 2004). Whereas IGF-IR activation did not stimulate
cell motility in T47D-YA cells, IGF-I was able to stimulate cell
motility in T47D-YA/IRS-2 cells (Figure 4). In contrast, IGF-I did
not stimulate cell motility in T47D-YA/IRS-1 cells, suggesting a
functional specificity of IRS-2 in IGF-IR-mediated cell motility.
Downregulation of insulin receptor substrate-1 diminished
response to insulin-like growth factor-I in MCF-7 cells
We have previously shown that downregulation of IRS-2 in MDA-
MB-231BO cells inhibited IGF-stimulated motility (Jackson et al,
2001). However, it has been more difficult to examine the function
of IRS-1 in breast cancer cells as stable transfection of an antisense
IRS-1 expression vector is not tolerated by breast cancer cells (data
not shown). To address this problem, we transiently transfected
IRS-1 siRNA into MCF-7 cells. As shown in Figure 5A, IRS-1
siRNA downregulated IRS-1 whereas an IRS-2 construct did not.
Signalling downstream of IRS-1 was inhibited proportionally to the
level of IRS-1 downregulation (data not shown). Inhibition of
IRS-1 diminished IGF-I-stimulated growth (Figure 5B). In contrast,
a NF and IRS-2 siRNA had no effect on IGF-I stimulation. It is
noteworthy that downregulation of IRS-1 also inhibited the basal
growth of MCF-7 cell suggesting an important role for this protein
even in the absence of IGF-signalling. Taken with our previously
published reports, these data support a role for IRS-1, but not IRS-
2, in IGF-stimulated growth of breast cancer cells.
Insulin receptor substrate-1 and -2 selectively coupled the
insulin-like growth factor receptor to downstream
pathways
We next sought to investigate the mechanistic basis for the specific
biological actions of IRS-1 and -2. To verify that both IRS-1 and -2
were functionally competent to participate in IGF-IR signalling,
tyrosine phosphorylated IRS-1 or -2 was detected by immunopre-
cipitation and anti-phosphotyrosine immunoblotting. As shown in
Figure 6A, each of the T47D-YA/IRS-1 cell clones exhibited IGF-I-
stimulated tyrosine phosphorylation of IRS-1. In addition, IRS-2
was phosphorylated upon IGF-I stimulation in each of the IRS-2-
transfected cell clones (Figure 6B). Insulin-like growth factor-I
treatment did not result in tyrosine phosphorylation of IRS-1 or -2
in T47D-YA cells, as was expected owing to the lack of IRS-1 and -2
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Figure 2 IRS-1 and -2 were stably expressed in T47D-YA cells. (A)
T47D-YA cells were stably transfected with a cDNA construct encoding
HA-tagged human IRS-1. Insulin receptor substrate-1 expression was
determined by immunoblot. (B) T47D-YA cells were stably transfected
with a cDNA construct encoding HA-tagged human IRS-2. Insulin receptor
substrate-2 expression was determined by immunoblot.
WT YA #5 #10 #20 #10
0
1
2
3
*
* *
*
T47D-YA IRS-1 T47D-YA IRS-2
SFM
IGF
%
 
O
f
 
c
e
l
l
s
 
i
n
 
S
+
G
2
M
(
f
o
l
d
 
i
n
c
r
e
a
s
e
)
WT YA vector #5 #8 #10 #20 #6 #10
0
1
2
3
4
5 A
B
C
SFM
IGF
T47D-YA IRS-1
*
*
*
*
*
T47D-YA IRS-2
A
b
s
o
r
b
a
n
c
e
 
a
t
 
5
7
0
 
n
m
(
f
o
l
d
 
i
n
c
r
e
a
s
e
)
T47D-YA #5 #8 #10 #20 #6 #10
0
1
2
3
− IGF 
+ IGF *
*
* *
T47D-YA IRS-1 T47D-YA IRS-2
N
u
m
b
e
r
 
o
f
 
c
o
l
o
n
i
e
s
(
f
o
l
d
 
i
n
c
r
e
a
s
e
)
Figure 3 IRS-1, but not IRS-2, expression resulted in IGF-I mediated cell
proliferation in T47D-YA cells. (A) T47D-YA/IRS-1 cell clones and T47D-
YA/IRS-2 cell clones were plated in 24-well plates in serum-containing
media, switched to SFM after 24h, and treated with or without 5nM IGF-I.
After 6 days, cell number was estimated using an MTT assay. Data are
represented as fold increase over each cell line’s SFM readings. Error bars
represent s.e. of the mean and * represents a significant difference
(Po0.05) in absorbance in samples treated with IGF-I compared to SFM.
P-values: T47D-YA/IRS-1 #5 (P¼0.0013); T47D-YA/IRS-1 #8
(P¼0.0265); T47D-YA/IRS-1 #10 (P¼0.0107); T47D-YA/IRS-1 #20
(P¼0.0247); T47D-WT (P¼0.0055). Data are representative of three
independent experiments. (B) T47D-YA/IRS-1 and T47D-YA/IRS-2 cells
were plated in 60mm dishes in serum-containing media and, after 24h,
switched to SFM for 48h. Cells were then treated with or without 5nM
IGF-I in SFM for 24h, stained with propidium iodide, and analysed for phase
of the cell cycle by flow cytometry. Error bars represent s.e. of the mean
and * represents a significant difference (Po0.05) in % of cells in SþG2M
phases of the cell cycle in samples treated with IGF-I compared to SFM. P-
values: T47D-WT (P¼0.045), T47D-YA/IRS-1 #5 (P¼0.020), T47D-YA/
IRS-1 #10 (P¼0.0317 ), T47D-YA/IRS-1 #20 (P¼0.0483). (C) A bottom
agar was prepared and overlaid with 800ml of a 0.45% top agar mixture
containing 10000 cells per well in the presence or absence of 5nM IGF-I
treatment and plates incubated at 371C. After 14 days, colonies formed in
the soft agar assay were counted using a light microscope with an ocular
grid. Only colonies larger than two-thirds of a grid square were counted.
Five random fields were counted for each well and the average number of
colonies per well calculated. Results are presented as fold increase over
each cell line’s SFM values. Results are representative of three experiments
performed in triplicate for each treatment. Error bars represent s.e. of the
mean and * represents a significant difference (Po0.05) in samples treated
with IGF-I compared to SFM. P-values: T47D-YA/IRS-1 #5 (P¼0.0078),
T47D-YA/IRS-1 #8 (P¼0.0086 ), T47D-YA/IRS-1 #10 (P¼0.0119),
T47D-YA/IRS-1 #20 (P¼0.0034).
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able to participate in IGF-IR signalling.
To determine whether IRS-1 and -2 couple IGF-IR to distinct
downstream pathways, we used phosphorylation-specific anti-
bodies to measure activation of PI3K and MAPK pathways, two of
the predominant signalling pathways activated by IGF-IR. In
T47D-YA/IRS-1 cells, IGF-I stimulated phosphorylation of both
Akt (a downstream target of PI3K activation) and MAPK
(Figure 6C). However, in T47D-YA/IRS-2 cells, IGF-I stimulated
phosphorylation of Akt, but not MAPK (Figure 6D). Together,
these data suggest that, whereas both IRS-1 and -2 couple IGF-IR
to PI3K activation in T47D-YA cells, IRS-1 may selectively couple
IGF-IR to MAPK activation.
Insulin receptor substrate-1 and -2 were required for
sensitivity to anti-insulin-like growth factor receptor
strategies
Given the current development of anti-IGF-IR strategies in clinical
trials, we next sought to determine whether expression of IRS
proteins was required for cell sensitivity to IGF-IR inhibition. To
address this question, we utilised aIR-3, a monoclonal antibody
targeted against IGF-IR that has previously been shown to disrupt
IGF-IR signalling and inhibit growth of some breast cancer cells
both in vitro and in vivo (Arteaga, 1992). As shown in Figure 7A,
aIR-3 inhibited IGF-I stimulation of monolayer growth in T47D-
YA/IRS-1 cells, but did not affect the monolayer growth of
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Figure 5 Downregulation of IRS-1 inhibited response to IGF-I in MCF-7
cells. (A) MCF-7 breast cancer cells were transfected with IRS-1, IRS-2 or
nonfunctional (NF) control siRNA constructs. After 24h, cells were lysed
and examined for IRS-1 expression by immunoblotting. Total MAPK was
used as a loading control. (B) Effect of IRS-1 downregulation on IGF-I-
stimulated growth was examined in 96-well plates. Cells were transfected
with a NF, IRS-1 or IRS-2 siRNA for 6h. Non-transfected (NT) cells were
also examined. After incubation in SFM overnight, cells were treated in the
absence (open bar) or presence (black bar) of 5nM IGF-I. Cell number was
estimated at this time point (day 0) by MTT assay. After 48h, cell numbers
were again determined and results are presented as percent increase over
day 0. These treatments were carried out in triplicate and results were
repeated. A representative experiment is shown. Statistically significant
differences are shown.
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Figure 4 Expression of IRS-2, but not IRS-1, resulted in IGF-I-stimulated
motility in T47D-YA cells. T47D-YA/IRS-1 and T47D-YA/IRS-2 cells were
plated on gold particle-coated coverslips. The cells were allowed to adhere,
treatment of SFM with or without 5nM IGF-I added, and cells incubated at
371C for 24h. Coverslip images were captured using a brightfield
microscope with a neutral density filter and the area on the coverslip
cleared by cell movement was computed using Simple PCI software. Data
are presented as mean area cleared. Error bars represent s.e. of the mean
and * represents a significant difference (Po0.05) in samples treated with
IGF-I compared to SFM. P-values: YA/IRS-2 #6 (P¼0.0224); YA/IRS-2 #10
(P¼0.0481); Results are representative of three independent experiments.
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Figure 6 IRS-1 and -2 selectively coupled the IGF-IR to downstream
pathways. (A) T47D-YA/IRS-1 cells were stimulated with 5nM IGF-I for
10min and cell lysates analysed for activated IRS-1 by immunoprecipitating
IRS-1, followed by immunoblotting for phosphorylated tyrosine residues.
(B) T47D-YA/IRS-2 cells were stimulated with 5nM IGF-I for 10min and
cell lysates analysed for activated IRS-2 by immunoprecipitating IRS-2,
followed by immunoblotting for phosphorylated tyrosine residues. (C)
T47D-YA/IRS-1 cells were examined by immunoblot for MAPK and PI3K
activation using phosphorylation specific antibodies following treatment
with 5nM IGF-I for 10min. (D) T47D-YA/IRS-2 cell clones were examined
by immunoblot for MAPK and PI3K activation after treatment with 5nM
IGF-I for 10min. Experiments were repeated a minimum of three times,
and representative blots shown.
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also inhibited IGF-I-stimulated cell motility in the T47D-YA/IRS-2
cells, yet did not inhibit cell motility in T47D-YA or T47D-YA/IRS-
1 cells (Figure 7B). Together, these data suggest that the biological
response to IGF-I stimulation, as well as sensitivity to an anti-IGF-
IR agent, is dependent not only on expression of functional IGF-
IR, but also on expression of the appropriate adaptor molecule.
DISCUSSION
Our previous data suggested that the IRS proteins were the
predominant molecules phosphorylated by IGF-IR in breast cancer
cells. Here, we show that IGF-IR requires these adaptor molecules
to mediate its biological effects, as exemplified by the lack of IGF-
IR stimulated proliferation or motility in T47D-YA cells, which
lack IRS-1 and -2 expression, yet express biochemically functional
IGF-IR. Among cancer cell lines, the T47D-YA cells are unique.
Variants of MCF-7 cells selected for loss of oestrogen receptor lose
both IGF-IR and IRS-1 expression, the T47D variants lose only the
adaptor proteins (Oesterreich et al, 2001), Thus, they represent an
ideal system to study the specific function of IGF-IR with and
without expression of the specific adaptor proteins. Our data
provide direct evidence that IRS-1 and -2 couple the IGF-IR to
distinct phenotypes, with IRS-1 specifically mediating IGF-IR-
stimulated proliferation, and IRS-2 mediating the motility actions
of the IGF-IR.
Our results demonstrate that stable expression of IRS-1 in T47D-
YA cells restores IGF-IR signalling through IRS-1 and sensitises
these cells to IGF-I-stimulated proliferation. In contrast to T47D-
YA/IRS-1 cells, T47D-YA/IRS-2 cells did not proliferate in
response to IGF-I. In breast cancer cells, IRS-1 overexpression
has been associated with tumour development and hormone
independence (Surmacz, 2000). In addition, high levels of IRS-1
expression have been shown to correlate with early disease
recurrence in oestrogen receptor-positive primary breast tumours
(Rocha et al, 1997; Lee et al, 1999). Importantly, our results suggest
that growth regulation of breast cancer by the IGF-IR is specifically
dependent on IRS-1-mediated signalling. Downregulation of IRS-1
is not well tolerated by breast cancer cells. However, our data using
transient transfection in MCF-7 cells suggest that IRS-1 is the key
regulator of IGF-IR-stimulated proliferation.
Our data also support a specific functional role for IRS-2 in IGF-
IR-stimulated cell motility. Previous work in our lab suggests a
role for IRS-2 in mediating cell motility in highly metastatic breast
cancer cell lines (Jackson et al, 2001). Furthermore, elegant studies
by Nagle et al (2004) recently used a mouse model of mammary
tumorigenesis and IRS-2-null mice to conclude that IRS-2 is an
important mediator of mammary tumour metastasis. Here,
expression of IRS-2 in T47D-YA cells coupled IGF-IR to
stimulation of cell motility, whereas IRS-1 expression did not
enhance the motility response of T47D-YA cells to IGF-I. Despite
the consistency of these data, reports from other labs have
suggested a role for IRS-1 in increasing cell adhesion and
decreasing cell motility in prostate cancer cells (Reiss et al,
2001). This may be a cell type specific effect or require interplay
with pathways not expressed in T47D breast cancer cells.
Furthermore, cell migration is a highly complex process (Shaw,
2001; Zhang et al, 2004). In our model system, we used fibronectin
to engage specific integrin receptors. It is possible that motility
mediated through other pathways, such as IRS-1, could be
dependent on integrin attachment to other extracellular matrix
substrates.
The specificity of IRS-1 and -2 to mediate IGF-IR-stimulated
proliferation and motility, respectively, may be a result of coupling
the IGF-IR to distinct downstream signalling pathways. Data
presented here suggest that, whereas both IRS-1 and -2 couple to
PI3K activation, IGF-IR stimulates MAPK signalling only in T47D-
YA cells expressing IRS-1. Indeed, a direct correlation between
IRS-1 tyrosine phosphorylation levels, activation of PI3K and
MAPK, and cell proliferation has been observed (Lee et al, 1999).
Furthermore, chemical inhibition of PI3K and MAPK (using
LY294002 and UO126, respectively) was sufficient to inhibit IGF-I-
stimulated entry into S phase in T47D-YA/IRS-1 cells (data not
shown), suggesting that activation of both MAPK and PI3K
pathways is required for IRS-1 to link IGF-IR to IGF-I-stimulated
proliferation.
However, we have also shown that IRS-1 expression alone is
insufficient to couple IGF-IR signalling to proliferative pathways in
all cells. We have previously transfected the MDA-MB-468 and
MDA-MB-435 cell lines with IRS-1 (Jackson and Yee, 1999). MDA-
MB-468 cells have been shown to be deficient in IRS-1 expression
(Sepp-Lorenzino et al, 1994). MDA-MB-435 cells are unable to
proliferate in response to IGF-I (Sachdev et al, 2004), yet have IGF-
stimulated motility. Both of these cell lines have constitutively
active MAPK. Thus, the ability of IRS-1 to stimulate proliferation
may lie in the ability of this adaptor protein to couple IGF-IR
activation to MAPK. If cells already have other pathways that
activate MAPK, then the role of IGF-IR/IRS-1 is likely superfluous.
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Figure 7 IRS-1 and -2 were required for sensitivity to anti-IGF-IR
strategies. (A) T47D-YA, T47D-YA/IRS-1, and T47D-YA/IRS-2 cells were
plated in triplicate in 24-well tissue culture plates at a density of 10000 cells
per well in growth media. After 24h, cells were washed twice with 1 
PBS and switched to SFM for 24h. Cells were then treated with SFM,
3mgml
 1 aIR-3, 5nM IGF-I or 3mgml
 1 aIR-3 plus 5nM IGF-I for 5 days and
cell number estimated using the MTT assay. Data are represented as fold
increase over each cell line’s SFM readings. Error bars represent s.e. of the
mean and * represents a significant difference (Po0.05) in absorbance in
samples treated with IGF-I compared to SFM. P-values: T47D-YA/IRS-1
#20 (P¼0.0141). Data are representative of three independent experi-
ments. (B) T47D-YA, T47D-YA/IRS-1 and T47D-YA/IRS-2 cells were
plated on gold particle-coated coverslips. Cells were allowed to adhere and
then treated with SFM, 3mgml
 1 aIR-3, 5nM IGF-I or 3mgml
 1 aIR-3 plus
5n M IGF-I for 24h. Coverslip images were captured using a brightfield
microscope with a neutral density filter and the area on the coverslip
cleared by cell movement was computed using Simple PCI software. Data
are presented as fold increase of the mean area cleared compared to each
cell line’s SFM readings. Error bars represent s.e. of the mean and
* represents a significant difference (Po0.05) in samples treated with IGF-I
compared to SFM. P-values: YA/IRS-2 #10 (P¼0.0169). Results are
representative of three independent experiments.
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function of IRS proteins in cells merely by introducing the protein
into IRS-deficient cell lines. Although this approach can success-
fully identify signalling pathways initiated by IRS proteins (Wang
et al, 1993; Sun et al, 1997; Valentinis et al, 2000), our data show it
may be difficult to discern the biology regulated by these activated
pathways using cells that never expressed these proteins.
Insulin-like growth factor-I treatment did not stimulate MAPK
signalling in T47D-YA/IRS-2 cells, suggesting that IGF-IR stimula-
tion of cell motility does not require stimulation of MAPK
signalling. Recent work from our lab and others suggests that
activation of multiple signalling pathways is required for IGF-IR
stimulation of cell motility (Zhang et al, 2005). In the highly
metastatic MDA-231BO cell line, IGF-IR stimulation of cell motility
is dependent on IRS-2 expression, PI3K and p38 activation and
integrin ligation (Jackson et al, 2001; Zhang and Yee, 2002; Zhang
et al, 2004; Zhang et al, 2005). However, we were unable to show
p38 activation in T47D-YA/IRS-2 cells (data not shown), suggest-
ing that the mechanism of IGF-IR-mediated motility is cell-type
dependent. Thus, the capacity of IRS-2 to mediate IGF-IR-
stimulated cell motility is likely dependent on selective coupling
to activation of additional required downstream signalling path-
ways that remain to be determined.
These findings have important implications, as several agents
targeting IGF-IR are currently in Phase I clinical trials. In breast
cancer, the value of measuring relevant biomarkers in the conduct
of clinical trials has been well documented. As modelled by Pegram
et al (2005) patient selection for the testing of novel cancer
therapeutics is critical. As agents targeting the IGF-IR prepare to
enter Phase II clinical trials, we must thoughtfully consider how to
best select patients with tumours dependent on IGF-IR. Our data
presented here suggest that expression of biochemically functional
IGF-IR alone may not couple to clinically measurable phenotypes.
This is well illustrated by the T47D-YA breast cancer cells, which
express and activate IGF-IR, but fail to translate this activation into
stimulation of biologically relevant responses. Indeed, we demon-
strate here that aIR-3, an inhibitor of IGF-IR, did not inhibit
monolayer growth or cell motility of T47D-YA cells. However,
introduction of IRS-1 or -2 expression in T47D-YA cells was
sufficient to introduce sensitivity to aIR-3, suggesting that
expression of appropriate adaptor molecules, in addition to
functional receptor, may be necessary to observe a response to
therapeutic agents targeting IGF-IR.
The success of anticancer agents in phase II clinical trials is
typically measured by objective tumour response rate, and does
not take into account alterations in other tumour phenotypes, such
as cancer metastasis. Our data show that expression of specific
adaptor proteins downstream of IGF-IR regulates distinct pheno-
types. Although both IRS-1 and -2 regulate the biological effects
of IGF-IR, only inhibition of proliferation is commonly measured
in phase II clinical trials. Thus, we propose that IRS-1 expression,
by linking IGF-IR to downstream signalling pathways required
for proliferation, may serve as a functional biomarker of IGF-IR
activity. At a minimum, measurement of key adaptor proteins
(IRS-1, IRS-2, phospho MAPK and phospho Akt), in addition
to measurement of receptor expression, should be considered
when conducting clinical trials of IGF-IR antagonists. Detection of
these proteins in formalin-fixed tissue would be ideal and
validation of reagents to detect these proteins must be carefully
performed.
In summary, we provide evidence that, though a functional IGF-
IR is a necessary mediator of IGF-I action, biological signalling of
the IGF-IR requires expression of appropriate adaptor molecules
suggesting that determination of IGF-IR expression is insufficient
to predict IGF-IR dependency of a tumour. Furthermore, the
cellular response following IGF-IR stimulation is dependent on the
species of IRS utilised by the IGF-IR, with IRS-1 mediating IGF-IR-
stimulated proliferation and IRS-2 mediating IGF-IR-stimulated
cell motility. Thus, the requirement of IRS expression for IGF-IR
action reported here should be considered to effectively design
Phase II clinical trials for agents targeting the IGF-IR. By coupling
IGF-IR activation to proliferative pathways, expression of IRS-1
could identify tumours that are most likely to respond to IGF-IR
inhibition.
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